[go: up one dir, main page]

Shan et al., 2012 - Google Patents

Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a postmortem study

Shan et al., 2012

View PDF
Document ID
3174835150812571207
Author
Shan L
Bossers K
Luchetti S
Balesar R
Lethbridge N
Chazot P
Bao A
Swaab D
Publication year
Publication venue
Neurobiology of aging

External Links

Snippet

Earlier studies showed neuronal histamine production in the hypothalamic tuberomamillary nucleus to be unchanged in Parkinson's disease (PD), whereas the histamine levels and innervation in the substantia nigra (SN) increased. In the present study we used quantitative …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Similar Documents

Publication Publication Date Title
Shan et al. Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a postmortem study
Hall et al. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson’s disease
JP5823964B2 (en) Methods for diagnosing and treating autism
BRPI0718413A2 (en) METHODS FOR PREDICTING SENSITIVITY OF A CONCEROUS CELL TO A FIRST ANTICCAN AGENT, TO PREDICT OR MONITOR EFFECTIVENESS OF AN ANTICAN AGENT, AND TO DETERMINE AN EFFECTIVE DOSE FOR ANTICCAN AGENT, DETECTION KIT, AND AXIS, A SYSTEM OF DETECTION
Datta et al. Quantitative neuroproteomics of an in vivo rodent model of focal cerebral ischemia/reperfusion injury reveals a temporal regulation of novel pathophysiological molecular markers
US6884591B2 (en) Peripheral marker of blood brain barrier permeability
KR101873499B1 (en) A biomarker for diagnosing vascular diseases and the uses thereof
JP5701994B2 (en) Citrullinated proteins: post-translational modification of myocardial proteins as markers of physiological and pathological diseases
Lei et al. Protein O-GlcNAcylation coupled to Hippo signaling drives vascular dysfunction in diabetic retinopathy
US20200138951A1 (en) Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
WO2018183213A1 (en) Blood biomarkers and diagnostic methods for small vessel diseases
Zhang et al. Spermidine mediates acetylhypusination of RIPK1 to suppress diabetes onset and progression
Hodes et al. Na+, K+-ATPase α3 isoform in frontal cortex GABAergic neurons in psychiatric diseases
Yuan et al. Analysis of the clinical diagnostic value of GMFB in cerebral infarction
Wang et al. Coexpression of MAST205 inhibits the activity of Na+/H+ exchanger NHE3
Güzel et al. Cerebrospinal fluid of preeclamptic and normotensive pregnant women compared to nonpregnant women analyzed with mass spectrometry
US20230144446A1 (en) Blood-based diagnostic assays for alzheimer's disease
Cao et al. Reactivation of Mthfd2 during heart failure drives cardiac remodeling
Chai et al. A novel Transcript is Up‐Regulated by Fasting in the Hypothalamus and Enhances Insulin Signalling
Delaidelli et al. α-Synuclein pathology in Parkinson disease activates homeostatic NRF2 anti-oxidant
CN117795340A (en) Biomarkers and their uses
Hindges et al. MyosinV controls PTEN function and neuronal cell size
Escher Proteomic profiling of Duchenne muscular dystrophy: Protein patterns and candidate markers of disease
HK1171080A (en) Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
JP2011215091A (en) Method for screening substance inhibiting c-met enzyme activity